You are here: Home: Audio Program Guide: BCU Surgeons 1 | 2008 Audio: BCU Surgeons 1 | 2008
 
  Go to interview with Monica Morrow, MD
Go to interview with Ian E Smith, MD
Go to interview with Robert W Carlson, MD
Go to interview with Soonmyung Paik, MD
  To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Morrow, MD Monica Morrow, MD
Chief, Breast Surgery and
Co-Director, Breast Program
Memorial Sloan-Kettering
Cancer Center
Professor of Surgery
Weill Cornell Medical College
New York, New York
  
  Click here to download the entire interview  
Track 1 Use of tamoxifen as chemoprevention for women at increased risk for breast cancer
Track 2 NSABP-P-2 (STAR): Tamoxifen versus raloxifene as chemoprevention
Track 3 Identifying women who may benefit from chemoprevention
Track 4 ATAC 100-month update: Implications for the investigation of aromatase inhibitors for chemoprevention
Track 5 Long-term natural history of hormone receptor-positive breast cancer: Implications for extended adjuvant therapy
Track 6 Reliability of ER, PR and HER2 assays

Track 7 Quantitative assessment of ER and HER2 using RT-PCR in the Oncotype DX™ assay
Track 8 New data on the use of the Oncotype DX assay for postmenopausal patients with hormone receptor-positive, node-positive breast cancer
audio
Track 9 Local therapy and survival in breast cancer
audio
Track 10 Synergy between the effectiveness of local therapy and systemic therapy
audio
Track 11 EBCTCG Overview: Benefit of radiation therapy for patients with one to three positive nodes
audio
Track 12 Neoadjuvant chemotherapy to allow breast-conserving surgery
audio
Track 13 Underutilization of neoadjuvant hormonal therapy in the US
Track 14 Sentinel lymph node biopsy (SLNB) for patients receiving neoadjuvant therapy
Track 15 Magnetic resonance imaging and breast cancer
audio
Track 16 Defining “negative margins” in breast tumor resection
audio
Track 17 Caveats in the use of partial breast irradiation off protocol
audio
Track 18 “Oncoplastic” surgical techniques in the treatment of breast cancer
audio
Track 19 Excision of the primary tumor in patients presenting with metastatic breast cancer
     
Smith, MD Ian E Smith, MD
Professor of Cancer Medicine
Department of Medicine
Breast Unit
The Royal Marsden Hospital
London and Surrey
United Kingdom
  
  Click here to download the entire interview  
Track 1 Neoadjuvant endocrine therapy
Track 2 Tumor response and biology as prognostic factors after neoadjuvant endocrine therapy
Track 3 Extended adjuvant endocrine therapy with aromatase inhibitors
Track 4 Preliminary ATLAS results: Ten years versus five years of adjuvant tamoxifen
Track 5 Switching from tamoxifen to an aromatase inhibitor when patients become amenorrheic
Track 6 European perspective on the Oncotype DX assay

Track 7 Pathologic complete response rate with neoadjuvant chemotherapy and trastuzumab for HER2-positive tumors
Track 8 Considerations in selecting an adjuvant chemotherapy/trastuzumab regimen
Track 9 Treatment of small, node-negative, HER2-positive tumors
Track 10 Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial
Track 11 Increased investigation of combined biologic therapies
Track 12 CIRG/NSABP BETH trial: Chemotherapy and trastuzumab with or without bevacizumab in HER2-positive early breast cancer
Track 13 Increasing treatment options for HER2-positive breast cancer
     
Carlson, MD Robert W Carlson, MD
Professor of Medicine
Division of Oncology and
Stanford Medical Informatics
Stanford University
Medical Center
Stanford, California
  
  Click here to download the entire interview  
Track 1 Adjuvant endocrine therapy for pre- and postmenopausal patients
Track 2 Extended adjuvant endocrine therapy beyond five years
Track 3 Carryover antitumor effect with anastrozole in long-term follow-up from the ATAC trial
Track 4 Long-term safety data from the ATAC trial
Track 5 Changing landscape in the care of patients receiving adjuvant endocrine therapy
Track 6 Implications of the long natural history of hormone receptor-positive breast cancer
audio
Track 7 Delayed, extended treatment with aromatase inhibitors after completion of adjuvant tamoxifen
audio
Track 8 Assessment of women who develop chemotherapy- or age-related menopause
audio
Track 9 Hormone receptor positivity and benefit from adjuvant chemotherapy
audio
Track 10 Potential value of the Oncotype DX assay in providing quantitative assessment of ER and HER2
Track 11 Clinical use of the Oncotype DX assay
Track 12 Emerging data with the Oncotype DX assay for patients with hormone receptor-positive, node-positive early breast cancer
Track 13 Molecular profiling with the MammaPrint® assay
Track 14 Overview of benefit from adjuvant trastuzumab in HER2-positive breast cancer
audio
Track 15 Guidelines and quality control for the assessment of HER2 status
audio
Track 16 Cardiotoxicity associated with chemotherapy and trastuzumab
audio
Track 17 Treatment algorithm for node-negative, HER2-positive tumors
audio
     
Paik, MD Soonmyung Paik, MD
Director, Division of Pathology
National Surgical Adjuvant
Breast and Bowel Project
Pittsburgh, Pennsylvania
  
  Click here to download the entire discussion  
Track 1 Quality control in ER and HER2 testing
Track 2 Variability in the assessment of ER
Track 3 Discordance rates in ER and HER2 testing
Track 4 Review of technologies used to assess ER and HER2
Track 5 Quantitative assessment of ER with the Oncotype DX assay
audio
Track 6 Development of the Oncotype DX assay
audio
Track 7 Oncotype DX predicts benefit from adjuvant chemotherapy for postmenopausal patients with hormone receptor-positive breast cancer
audio
Track 8 Gene expression by Oncotype DX in special histologic subtypes of hormone receptor-positive breast cancer
audio
Track 9 Use of the Oncotype DX assay for patients with rare histologic subtypes of hormone receptor-positive breast cancer
audio